Literature DB >> 18768497

Serum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey.

Halcyon G Skinner1, Gary G Schwartz.   

Abstract

We examined the association between serum calcium levels and the risk for prostate cancer using a prospective cohort, the National Health and Nutrition Examination Survey (NHANES) and the NHANES Epidemiologic Follow-up Study. Eighty-five incident cases of prostate cancer and 25 prostate cancer deaths occurred over 46,188 person-years of follow-up. Serum calcium was determined an average of 9.9 years before the diagnosis of prostate cancer. Comparing men in the top with men in the bottom tertile of serum calcium, the multivariable-adjusted relative hazard for fatal prostate cancer was 2.68 (95% confidence interval, 1.02-6.99; P(trend) = 0.04). For incident prostate cancer, the relative risk for the same comparison was 1.31 (95% confidence interval, 0.77-2.20; P(trend) = 0.34). These results support the hypothesis that high serum calcium or a factor strongly associated with it (e.g., high serum parathyroid hormone) increases the risk for fatal prostate cancer. Our finding of a >2.5-fold increased risk for men in the highest tertile of serum calcium is comparable in magnitude with the risk associated with family history and could add significantly to our ability to identify men at increased risk for fatal prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18768497      PMCID: PMC2760313          DOI: 10.1158/1055-9965.EPI-08-0365

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  17 in total

1.  A986S polymorphism of the calcium-sensing receptor and circulating calcium concentrations.

Authors:  D E Cole; V D Peltekova; L A Rubin; G A Hawker; R Vieth; C C Liew; D M Hwang; J Evrovski; G N Hendy
Journal:  Lancet       Date:  1999-01-09       Impact factor: 79.321

Review 2.  Primary hyperparathyroidism.

Authors:  A al Zahrani; M A Levine
Journal:  Lancet       Date:  1997-04-26       Impact factor: 79.321

3.  Serum calcium and survival in a large health screening program.

Authors:  B G Leifsson; B Ahrén
Journal:  J Clin Endocrinol Metab       Date:  1996-06       Impact factor: 5.958

4.  Plan and operation of the HANES I augmentation survey of adults 25-74 years United States, 1974-1975.

Authors:  A Engel; R S Murphy; K Maurer; E Collins
Journal:  Vital Health Stat 1       Date:  1978-06

5.  Risk of prostate cancer in a randomized clinical trial of calcium supplementation.

Authors:  John A Baron; Michael Beach; Kristin Wallace; Maria V Grau; Robert S Sandler; Jack S Mandel; David Heber; E Robert Greenberg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-03       Impact factor: 4.254

6.  Calcium and fructose intake in relation to risk of prostate cancer.

Authors:  E Giovannucci; E B Rimm; A Wolk; A Ascherio; M J Stampfer; G A Colditz; W C Willett
Journal:  Cancer Res       Date:  1998-02-01       Impact factor: 12.701

7.  Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer.

Authors:  R M Murray; V Grill; N Crinis; P W Ho; J Davison; P Pitt
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

8.  Effects of the calciotrophic peptides calcitonin and parathyroid hormone on prostate cancer growth and chemotaxis.

Authors:  C K Ritchie; K G Thomas; L R Andrews; D J Tindall; L A Fitzpatrick
Journal:  Prostate       Date:  1997-02-15       Impact factor: 4.104

Review 9.  Vitamin D and intervention trials in prostate cancer: from theory to therapy.

Authors:  Gary G Schwartz
Journal:  Ann Epidemiol       Date:  2008-07-10       Impact factor: 3.797

10.  Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada.

Authors:  A S Whittemore; A H Wu; L N Kolonel; E M John; R P Gallagher; G R Howe; D W West; C Z Teh; T Stamey
Journal:  Am J Epidemiol       Date:  1995-04-15       Impact factor: 4.897

View more
  33 in total

Review 1.  [Physical activity for primary prevention of prostate cancer. Possible mechanisms].

Authors:  H C Heitkamp; I Jelas
Journal:  Urologe A       Date:  2012-04       Impact factor: 0.639

Review 2.  Lifestyle and dietary factors in the prevention of lethal prostate cancer.

Authors:  Kathryn M Wilson; Edward L Giovannucci; Lorelei A Mucci
Journal:  Asian J Androl       Date:  2012-04-16       Impact factor: 3.285

3.  Calcium intake, polymorphisms of the calcium-sensing receptor, and recurrent/aggressive prostate cancer.

Authors:  Moritz Binder; Irene M Shui; Kathryn M Wilson; Kathryn L Penney; Lorelei A Mucci; Adam S Kibel
Journal:  Cancer Causes Control       Date:  2015-09-25       Impact factor: 2.506

4.  Calcium intake and prostate cancer among African Americans: effect modification by vitamin D receptor calcium absorption genotype.

Authors:  Glovioell W Rowland; Gary G Schwartz; Esther M John; Sue Ann Ingles
Journal:  J Bone Miner Res       Date:  2012-01       Impact factor: 6.741

5.  Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone.

Authors:  Xin Li; Jinhui Liao; Serk In Park; Amy J Koh; William D Sadler; Kenneth J Pienta; Thomas J Rosol; Laurie K McCauley
Journal:  Bone       Date:  2011-03-17       Impact factor: 4.398

6.  Serum calcium, albumin and tumor stage in cutaneous malignant melanoma.

Authors:  Mridul Datta; Paul Savage; James Lovato; Gary G Schwartz
Journal:  Future Oncol       Date:  2016-06-16       Impact factor: 3.404

7.  Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression.

Authors:  Shu Feng; Olga Dakhova; Chad J Creighton; Michael Ittmann
Journal:  Cancer Res       Date:  2013-02-25       Impact factor: 12.701

8.  Association of serum calcium with serum sex steroid hormones in men in NHANES III.

Authors:  Mieke Van Hemelrijck; Karl Michaelsson; William G Nelson; Norma Kanarek; Adrian Dobs; Elizabeth A Platz; Sabine Rohrmann
Journal:  Aging Male       Date:  2013-05-14       Impact factor: 5.892

9.  The relation of serum parathyroid hormone and serum calcium to serum levels of prostate-specific antigen: a population-based study.

Authors:  Halcyon G Skinner; Gary G Schwartz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-27       Impact factor: 4.254

Review 10.  Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review.

Authors:  Mridul Datta; Gary G Schwartz
Journal:  Oncologist       Date:  2012-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.